Sugi Predict

Sugi Predict / Compounds / SCHEMBL6754569

SCHEMBL6754569

SCHEMBL6754569

CCCCNS(=O)(=O)C(C)C

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GRIA1 P42261 3/20 0.74
▸ CA1 P00915 5/20 0.58
▸ CA2 P00918 4/20 0.58
▸ CA12 O43570 2/20 0.58
▸ CA14 Q9ULX7 2/20 0.58
▸ CA7 P43166 1/20 0.58
▸ PPARA Q07869 4/20 0.45
▸ EPHX1 P07099 1/20 0.41
▸ GRIA4 P48058 1/20 0.41
▸ MEN1 O00255 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ADH1B P00325 1/20 0.36
▸ ADH1C P00326 1/20 0.36
▸ ADH1A P07327 1/20 0.36
▸ ADH7 P40394 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14654996 0.93 GRIA1 (0.78) GRIA1CA1CA2CA12CA14
SCHEMBL24735803 0.91 GRIA1 (0.83) GRIA1CA1CA2CA12CA14
SCHEMBL13959008 0.91 GRIA1 (0.83) GRIA1CA1CA2CA12CA14
SCHEMBL20734509 0.91 GRIA1 (0.83) GRIA1CA1CA2CA12CA14
SCHEMBL7039391 0.85 GRIA1 (1.00) GRIA1CA1CA2CA12CA14
SCHEMBL7042049 0.85 GRIA1 (1.00) GRIA1CA1CA2CA12CA14
SCHEMBL7109326 0.85 GRIA1 (1.00) GRIA1CA1CA2CA12CA14
SCHEMBL8366386 0.85 GRIA1 (0.65) GRIA1CA1CA2CA12CA14
SCHEMBL17771565 0.82 CA1 (0.54) GRIA1CA1CA2CA12CA14
SCHEMBL10147477 0.82 CA1 (0.54) GRIA1CA1CA2CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023168291-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-09-07 — — WO disclosed
EP-4198034-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Tuojie Biotech (Shanghai) Co., Ltd. (CN) 2023-06-21 — — EP disclosed
US-20220096649-A1 IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE HORIZON TECHNOLOGY FINANCE CORPORATION 2022-03-31 — — US disclosed
WO-2019147862-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF FLX BIO, INC. (US) 2019-08-01 — — WO disclosed
US-20150352108-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON ALZHEIMER'S INSTITUTE OF AMERICA (US) 2015-12-10 — — US disclosed
US-8338608-B2 Inhibitors of ion channels ICAGEN INC. (US) 2012-12-25 — — US disclosed
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 MYREXIS, INC. (US) 2012-09-20 — — US disclosed
US-20100234343-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2010-09-16 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7732416-B2 For protecting plants against parasitic feeding pests; also against the infestation of pets, especially cats and dogs, by fleas, ticks and nematodes; pesticides for crop protection MERIAL LIMITED (US) 2010-06-08 — — US disclosed
US-7705158-B2 Inhibitors of ion channels ICAGEN, INC. (US) 2010-04-27 — — US disclosed
US-7605134-B2 Pesticides MERIAL LIMITED (US) 2009-10-20 — — US disclosed
US-7605134-B2 Pesticides MERIAL LIMITED (US) 2009-10-20 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070135493-A1 INHIBITORS OF ION CHANNELS ICAGEN (US) 2007-06-14 — — US disclosed
US-6713473-B1 6-CARBAMATE-1,2,3,4-TETRAHYDROCARBAZOLE DERIVATIVES; AFFINITY FOR NEUROPEPTIDE Y RECEPTORS MEIJI SEIKA KAISHA, LTD. (JP) 2004-03-30 — — US disclosed
EP-1184373-A1 TRICYCLIC COMPOUNDS MEIJI SEIKA KAISHA LTD. (JP) 2002-03-06 — — EP disclosed
US-5545838-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1996-08-13 — — US disclosed
US-5098924-A Hypotensive agents and angiotensin II inhibitors E. R. SQUIBB & SONS, INC. (US) 1992-03-24 — — US disclosed
EP-0452587-A1 Dihydroxy sulfonamide and sulfinamide renin inhibitors E.R. SQUIBB & SONS, INC. (US) 1991-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234343-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 GRIA1 477/4885CA1 1063/4885CA2 169/4885
US-20150352108-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON TBK1, NFKBIA, CHUK GRIA1 3155/4885CA1 4866/4885CA2 3976/4885
US-20070135493-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 GRIA1 477/4885CA1 1063/4885CA2 169/4885
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 TBK1, NFKBIA, IKBKB GRIA1 3279/4885CA1 4823/4885CA2 4510/4885
US-20220096649-A1 IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE PBK, CD47, NCL GRIA1 3952/4885CA1 4810/4885CA2 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.